Loading...
aTyr Pharma, Inc.
ATYR•NASDAQ
Healthcare
Biotechnology
$5.83
$0.28(4.95%)
aTyr Pharma, Inc. (ATYR) Financial Performance & Income Statement Overview
Review aTyr Pharma, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-33.43%
↓ 33.43%
Operating Income Growth
-23.66%
↓ 23.66%
Net Income Growth
-27.06%
↓ 27.06%
Operating Cash Flow Growth
-108.06%
↓ 108.06%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-86.87%
↓ 86.87%
ROIC
-77.46%
↓ 77.46%
aTyr Pharma, Inc. (ATYR) Income Statement & Financial Overview
Review aTyr Pharma, Inc.'s (ATYR) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $235000.00 |
| Cost of Revenue | $0.00 | $0.00 | $383000.00 | $770000.00 |
| Gross Profit | $0.00 | $0.00 | -$383000.00 | -$535000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | -$2.28 | |
| R&D Expenses | $12.23M | $14.81M | $13.97M | $13.36M |
| SG&A Expenses | $3.59M | $3.34M | $3.34M | $2.74M |
| Operating Expenses | $15.82M | $18.14M | $3.34M | $16.10M |
| Total Costs & Expenses | $15.82M | $18.14M | $17.32M | $16.87M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | -$1000.00 | $388000.00 | $383000.00 | $770000.00 |
| EBITDA | -$15.82M | -$17.75M | -$16.93M | -$15.87M |
| EBITDA Ratio | -$67.51 | |||
| Operating Income | -$15.82M | -$18.14M | -$17.32M | -$16.64M |
| Operating Income Ratio | -$70.79 | |||
| Other Income/Expenses (Net) | $852000.00 | $882000.00 | $1.009M | $1.15M |
| Income Before Tax | -$14.97M | -$17.26M | -$16.31M | -$15.49M |
| Income Before Tax Ratio | -$65.90 | |||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $4000.00 |
| Net Income | -$14.97M | -$17.26M | -$16.31M | -$15.49M |
| Net Income Ratio | -$65.92 | |||
| EPS | -$0.20 | -$0.23 | -$0.23 | -$0.23 |
| Diluted EPS | -$0.20 | -$0.23 | -$0.23 | -$0.23 |
| Weighted Avg Shares Outstanding | $74.26M | $75.80M | $72.28M | $66.08M |
| Weighted Avg Shares Outstanding (Diluted) | $74.26M | $75.80M | $72.28M | $66.08M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan